- Home
- EXAS vs EPAM Comparison
EXAS vs EPAM Comparison
Compare EXAS & EPAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- EPAM
- Stock Information
- Founded
- EXAS 1995
- EPAM 1993
- Country
- EXAS United States
- EPAM United States
- Employees
- EXAS N/A
- EPAM N/A
- Industry
- EXAS Medical Specialities
- EPAM EDP Services
- Sector
- EXAS Health Care
- EPAM Technology
- Exchange
- EXAS Nasdaq
- EPAM Nasdaq
- Market Cap
- EXAS 12.3B
- EPAM 10.8B
- IPO Year
- EXAS N/A
- EPAM 2012
- Fundamental
- Price
- EXAS $49.33
- EPAM $235.35
- Analyst Decision
- EXAS Strong Buy
- EPAM Buy
- Analyst Count
- EXAS 17
- EPAM 21
- Target Price
- EXAS $73.07
- EPAM $263.75
- AVG Volume (30 Days)
- EXAS 3.3M
- EPAM 648.0K
- Earning Date
- EXAS 11-05-2024
- EPAM 11-07-2024
- Dividend Yield
- EXAS N/A
- EPAM N/A
- EPS Growth
- EXAS N/A
- EPAM N/A
- EPS
- EXAS N/A
- EPAM 7.70
- Revenue
- EXAS $2,692,328,000.00
- EPAM $4,636,846,000.00
- Revenue This Year
- EXAS $12.41
- EPAM $1.31
- Revenue Next Year
- EXAS $11.64
- EPAM $8.71
- P/E Ratio
- EXAS N/A
- EPAM $30.57
- Revenue Growth
- EXAS 11.91
- EPAM N/A
- 52 Week Low
- EXAS $40.62
- EPAM $169.43
- 52 Week High
- EXAS $79.62
- EPAM $317.50
- Technical
- Relative Strength Index (RSI)
- EXAS 22.62
- EPAM 67.85
- Support Level
- EXAS $48.02
- EPAM $187.64
- Resistance Level
- EXAS $52.32
- EPAM $249.50
- Average True Range (ATR)
- EXAS 2.86
- EPAM 6.60
- MACD
- EXAS -1.89
- EPAM 4.82
- Stochastic Oscillator
- EXAS 5.28
- EPAM 77.13
About EXAS Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.
About EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm that offers platform engineering, software development, and consulting services. EPAM's largest market is North America, which represents approximately 60% of revenues. Offerings span assisting companies with new technologies, such as artificial intelligence, virtual reality, and robotics.